Shares of Illumina, Inc. (NASDAQ:ILMN) have earned an average rating of “Buy” from the eighteen brokerages that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $346.97.

A number of equities research analysts have commented on the company. OTR Global cut Illumina to a “positive” rating in a report on Tuesday, April 2nd. Leerink Swann raised Illumina to an “outperform” rating and decreased their price target for the company from $380.00 to $365.00 in a report on Wednesday, January 30th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Monday, December 31st. BidaskClub cut Illumina from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Finally, UBS Group raised Illumina from a “neutral” rating to a “buy” rating and raised their price target for the company from $340.00 to $370.00 in a report on Thursday, January 3rd.

In other news, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction dated Wednesday, January 23rd. The stock was sold at an average price of $303.53, for a total value of $1,001,649.00. Following the sale, the director now directly owns 329,979 shares of the company’s stock, valued at $100,158,525.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Aimee L. Hoyt sold 298 shares of Illumina stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $304.63, for a total value of $90,779.74. Following the completion of the sale, the senior vice president now directly owns 2,297 shares in the company, valued at $699,735.11. The disclosure for this sale can be found here. Insiders sold 34,826 shares of company stock worth $10,604,560 over the last ninety days. Insiders own 0.38% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jupiter Wealth Management LLC bought a new stake in Illumina during the first quarter worth approximately $387,000. Clear Harbor Asset Management LLC boosted its position in shares of Illumina by 0.4% during the first quarter. Clear Harbor Asset Management LLC now owns 11,150 shares of the life sciences company’s stock valued at $3,464,000 after buying an additional 46 shares during the period. Financial Gravity Wealth Inc. purchased a new position in shares of Illumina during the first quarter valued at approximately $234,000. Starfire Investment Advisers Inc. boosted its position in shares of Illumina by 69.6% during the first quarter. Starfire Investment Advisers Inc. now owns 1,950 shares of the life sciences company’s stock valued at $605,000 after buying an additional 800 shares during the period. Finally, Sage Rhino Capital LLC purchased a new position in shares of Illumina during the first quarter valued at approximately $307,000. 90.46% of the stock is currently owned by institutional investors.

NASDAQ:ILMN traded down $1.47 on Monday, reaching $317.56. 26,237 shares of the company’s stock traded hands, compared to its average volume of 902,653. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23. The stock has a market cap of $46.70 billion, a PE ratio of 55.55, a P/E/G ratio of 2.27 and a beta of 1.17. Illumina has a 12 month low of $226.62 and a 12 month high of $372.61.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.04). The business had revenue of $867.00 million for the quarter, compared to the consensus estimate of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. Illumina’s revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 earnings per share. Sell-side analysts anticipate that Illumina will post 6.53 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Further Reading: Preferred Stock

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.